MA52424B1 - Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide - Google Patents

Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide

Info

Publication number
MA52424B1
MA52424B1 MA52424A MA52424A MA52424B1 MA 52424 B1 MA52424 B1 MA 52424B1 MA 52424 A MA52424 A MA 52424A MA 52424 A MA52424 A MA 52424A MA 52424 B1 MA52424 B1 MA 52424B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
oxazepane
benzoxazol
carboxamide
dihydro
Prior art date
Application number
MA52424A
Other languages
English (en)
Other versions
MA52424A (fr
Inventor
Håkan WIKSTRÖM
Jufang Wu LUDVIGSSON
Thomas Andersson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA52424A publication Critical patent/MA52424A/fr
Publication of MA52424B1 publication Critical patent/MA52424B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques appropriées pour une administration orale, et plus particulièrement des compositions pharmaceutiques, notamment des compositions de comprimés pharmaceutiques, contenant du (2S)-N- { (1S)-1-cyano-2-[4- (3-méthyl-2-oxo-2,3-dihydro -1,3-benzoxazol-5-yl) phényl]éthyl}-1,4-oxazépane-2-carboxamide (composé A) ou un sel pharmaceutiquement acceptable de celui-ci.
MA52424A 2018-03-01 2019-03-01 Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide MA52424B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636944P 2018-03-01 2018-03-01
EP19716296.9A EP3758708B1 (fr) 2018-03-01 2019-03-01 Compositions pharmaceutiques comprenant du (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
PCT/EP2019/055138 WO2019166626A1 (fr) 2018-03-01 2019-03-01 Compositions pharmaceutiques comprenant du (2s)-n-{(1s)-1-cyano-2-[4-(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phényl]éthyl}-1,4-oxazépane-2-carboxamide

Publications (2)

Publication Number Publication Date
MA52424A MA52424A (fr) 2021-01-06
MA52424B1 true MA52424B1 (fr) 2025-04-30

Family

ID=66102025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52424A MA52424B1 (fr) 2018-03-01 2019-03-01 Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide

Country Status (21)

Country Link
US (3) US12059424B2 (fr)
EP (2) EP4516353A3 (fr)
JP (3) JP7336450B2 (fr)
KR (2) KR20250002710A (fr)
CN (3) CN112055593B (fr)
AU (3) AU2019228717C1 (fr)
CA (1) CA3091707A1 (fr)
DK (1) DK3758708T3 (fr)
ES (1) ES3011730T3 (fr)
FI (1) FI3758708T3 (fr)
HR (1) HRP20250115T1 (fr)
HU (1) HUE070049T2 (fr)
LT (1) LT3758708T (fr)
MA (1) MA52424B1 (fr)
MD (1) MD3758708T2 (fr)
PL (1) PL3758708T3 (fr)
PT (1) PT3758708T (fr)
RS (1) RS66494B1 (fr)
SI (1) SI3758708T1 (fr)
SM (1) SMT202500062T1 (fr)
WO (1) WO2019166626A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (fr) 2014-01-24 2018-02-24
KR20240091302A (ko) * 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
HUE070049T2 (hu) 2018-03-01 2025-05-28 Astrazeneca Ab (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
WO2020018547A1 (fr) 2018-07-17 2020-01-23 Insmed Incorporated Certains (2s)-n-[(1s)-1-cyano-2-phényléthyl]-1,4-oxazépane-2-carboxamides pour le traitement d'une néphropathie lupique
EP4182700A4 (fr) 2020-07-20 2024-11-13 Insmed Incorporated Procédés destinés à l'extraction de sérines protéases neutrophiles et de traitement de conditions induites par la dipeptidyle peptidase 1
US20240150335A1 (en) * 2021-02-05 2024-05-09 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane
US20240226112A1 (en) * 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CA3236069A1 (fr) * 2021-10-29 2023-05-04 Ariel Teper Utilisations de certains n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides pour traiter la rhino-sinusite chronique
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
EP4450497A4 (fr) * 2022-01-11 2025-11-26 Shanghai Yidian Pharmaceutical Tech Development Co Ltd Composé de peptidyle nitrile et son utilisation
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途
JP2026510407A (ja) * 2023-03-23 2026-04-02 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ小分子阻害剤を含む医薬組成物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
CA2422057C (fr) 2000-09-08 2012-11-27 Prozymex A/S Structure cristalline du dipeptidyl peptidase i et l'utilisation de celui-ci
US20110236367A1 (en) 2000-09-08 2011-09-29 Telenav, Inc. Rat cathespin dipeptidyl peptidase i (dppi): crystal structure and its uses
EP1217000A1 (fr) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibiteurs du factor Xa et factor VIIa
HUP0402344A2 (hu) 2001-12-04 2005-02-28 F. Hoffmann-La Roche Ag Helyettesített 2-amino-cikloalkán-karboxamidok, felhasználásuk cisztein-proteáz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (fr) 2003-02-28 2004-09-10 Aic Inhibiteurs de dipeptidyl peptidases
WO2004087153A2 (fr) 2003-03-28 2004-10-14 Chiron Corporation Utilisation de petites molecules de composes pour une immunopotentialisation
EP1633702B1 (fr) 2003-05-30 2008-07-02 Prozymex A/S Inhibiteurs de protease
JP2006527704A (ja) 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
EP3372614B1 (fr) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Méthodes de traitement de la douleur associée au cancer des os par administration d'un antagoniste des facteurs de croissance neuronale
EP1745292A2 (fr) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
PL1916994T3 (pl) 2004-06-29 2014-05-30 Takeda Pharma As Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
WO2007005668A2 (fr) 2005-06-30 2007-01-11 Amgen Inc. Inhibiteurs de bis-aryl kinase et methode associee
JP2010520293A (ja) 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 複素環式部分を含有するメタロプロテアーゼ阻害剤
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
MX2010003263A (es) 2007-09-25 2010-06-02 Novartis Ag Tratamiento de trastornos pulmonares con medicamentos aerosolizados tales como vancomicina.
US7902181B2 (en) 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
JP5752601B2 (ja) 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
BRPI1016132B8 (pt) 2009-04-01 2021-05-25 Bial Portela & Ca Sa composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
MX2011011661A (es) 2009-05-07 2011-11-18 Astrazeneca Ab Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
WO2010142985A1 (fr) 2009-06-10 2010-12-16 Astrazeneca Ab Composés 761 n-[1-cyano-2-(phényle)éthyle]pipéridine-2-ylcarboxamide substitués
HRP20211752T1 (hr) * 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2011154677A1 (fr) 2010-06-09 2011-12-15 Astrazeneca Ab Composés n-[1-cyano-2-(phényl)éthyl] 1-aminocycloalk-1-ylcarboxamide substitués - 760
WO2012119941A1 (fr) 2011-03-04 2012-09-13 Prozymex A/S Composés de peptidylnitrile à titre d'inhibiteurs de peptidases
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
CN104114557B (zh) 2012-02-21 2017-10-24 默克专利股份公司 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪
EP2840083B1 (fr) 2012-04-17 2017-09-13 Astellas Pharma Inc. Composé hétérocyclique aromatique bicyclique azoté
WO2014091443A1 (fr) 2012-12-13 2014-06-19 Glaxo Group Limited Inhibiteurs de la cathepsine c pour traiter la mucoviscidose, la bronchectasie sans fibrose kystique, et la vascularite associée aux anca
EP2775304A1 (fr) 2013-03-07 2014-09-10 Universitätsspital Basel Procédés de détection de troubles inflammatoires
EP2970252B1 (fr) 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH (benzyl-cyano-méthyl)-amides de l'acide 2-aza-bicyclo[2.2.2]octane-3-carboxylique substitués inhibiteurs de la cathepsine c
JP6437929B2 (ja) 2013-03-14 2018-12-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
ES2845473T3 (es) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
EP2970228B1 (fr) 2013-03-14 2017-05-10 Boehringer Ingelheim International GmbH Cyano-méthyl-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique en tant qu'inhibiteurs de la cathepsine c
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
WO2015027039A1 (fr) 2013-08-22 2015-02-26 Emory University Dispositifs et procédés relatifs à une inflammation des voies aériennes
EP3044214B1 (fr) 2013-09-09 2017-08-09 ProZymex A/S Composés de type peptidyle-nitrile en tant qu'inhibiteur de dipeptidyle peptidase i
WO2015032942A1 (fr) 2013-09-09 2015-03-12 Prozymex A/S 3,3'-(biphényl-4,4'-diyl)bis-2-aminopropanenitriles substitués en n en tant qu'inhibiteurs dppi
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (fr) 2014-01-24 2018-02-24
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
EP3129020A1 (fr) * 2014-04-10 2017-02-15 Novartis AG Régime posologique de modulateur s1p à libération immédiate
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
WO2015180687A1 (fr) 2014-05-30 2015-12-03 The University Of Hong Kong Procédés et compositions permettant d'utiliser l'élastase neutrophile et la protéinase 3 en tant que biomarqueurs de diagnostic
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
EP3511331A1 (fr) 2014-09-12 2019-07-17 Boehringer Ingelheim International GmbH Inhibiteurs spirocycliques de la cathepsine c
BR112017009595A2 (pt) 2014-11-14 2017-12-19 Boehringer Ingelheim Int morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
JP6783426B2 (ja) 2015-03-05 2020-11-11 ニュープロザイム・セラピューティクス・アンパルトセルスカブＮｅｕｐｒｏｚｙｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡｐＳ ジペプチジルペプチダーゼｉ阻害剤としてのペプチジルニトリル化合物
KR20240091302A (ko) * 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (fr) 2018-02-07 2019-08-15 Insmed Incorporated Certains (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides pour traiter les vascularites associees aux anca
HUE070049T2 (hu) 2018-03-01 2025-05-28 Astrazeneca Ab (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
US20210252015A1 (en) 2018-07-17 2021-08-19 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
WO2020018547A1 (fr) 2018-07-17 2020-01-23 Insmed Incorporated Certains (2s)-n-[(1s)-1-cyano-2-phényléthyl]-1,4-oxazépane-2-carboxamides pour le traitement d'une néphropathie lupique
MX2021012548A (es) 2019-04-17 2023-01-05 Azora Therapeutics Inc Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
WO2022140516A1 (fr) 2020-12-22 2022-06-30 Insmed Incorporated Certains ((25)-iv-[(ls')~ i-c yan0-2-phényléthyl·]-1,4-oxazépane-2-carboxamides pour le traitement de la maladie de behçet
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
US20240226112A1 (en) 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
WO2022232420A1 (fr) 2021-04-29 2022-11-03 Insmed Incorporated Certains n-(1-cyano-2-phényléthyl)-1,4-oxazépane-2-carboxamides pour le traitement du cancer
CA3236069A1 (fr) 2021-10-29 2023-05-04 Ariel Teper Utilisations de certains n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides pour traiter la rhino-sinusite chronique
EP4479059A4 (fr) 2022-02-16 2026-01-28 Insmed Inc Certains n-(1-cyano-2-phényléthyl)-1,4-oxazépane-2-carboxamides pour le traitement de l'hidradénite suppurée

Also Published As

Publication number Publication date
US12201638B2 (en) 2025-01-21
US20250108060A1 (en) 2025-04-03
US20240252512A1 (en) 2024-08-01
CN112055593B (zh) 2024-04-09
KR20250002710A (ko) 2025-01-07
PT3758708T (pt) 2025-02-13
EP4516353A3 (fr) 2025-05-21
WO2019166626A1 (fr) 2019-09-06
CN112055593A (zh) 2020-12-08
SMT202500062T1 (it) 2025-03-12
JP7336450B2 (ja) 2023-08-31
EP4516353A2 (fr) 2025-03-05
PL3758708T3 (pl) 2025-03-31
AU2024220121B2 (en) 2026-03-26
KR20210014621A (ko) 2021-02-09
JP2025134766A (ja) 2025-09-17
LT3758708T (lt) 2025-02-25
FI3758708T3 (fi) 2025-02-18
US12059424B2 (en) 2024-08-13
DK3758708T3 (da) 2025-02-24
ES3011730T3 (en) 2025-04-08
MA52424A (fr) 2021-01-06
AU2019228717C1 (en) 2025-01-09
KR102738945B1 (ko) 2024-12-04
US20210369732A1 (en) 2021-12-02
CA3091707A1 (fr) 2019-09-06
MD3758708T2 (ro) 2025-04-30
AU2024220121A1 (en) 2024-10-17
AU2026201419A1 (en) 2026-03-19
HRP20250115T1 (hr) 2025-05-23
HUE070049T2 (hu) 2025-05-28
EP3758708A1 (fr) 2021-01-06
JP2023156480A (ja) 2023-10-24
JP2021515006A (ja) 2021-06-17
EP3758708B1 (fr) 2024-11-27
CN118416078A (zh) 2024-08-02
AU2019228717A1 (en) 2020-09-17
AU2019228717B2 (en) 2024-07-04
RS66494B1 (sr) 2025-03-31
SI3758708T1 (sl) 2025-04-30
CN118416077A (zh) 2024-08-02

Similar Documents

Publication Publication Date Title
MA52424B1 (fr) Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
GEP20237506B (en) Pcsk9 antagonist compounds
TN2016000230A1 (en) Orally disintegrating solid dosage unit containing an estetrol component.
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
TNSN08139A1 (fr) Composes therapeutiques
DE60231911D1 (de) Sedierende und nicht sedierende antihistamine enthaltende zusammensetzungen
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA39164B1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
MA38358A1 (fr) Formulations de composés organiques
MX385820B (es) Unidad de dosificacion orodispersable que contiene un componente estetrol.
CO6531485A2 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
FI4101454T3 (fi) Koostumuksia käytettäviksi kohonneen verenpaineen hoitoon
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
MA50201B1 (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
CR20220199A (es) Inhibidores del factor d del complemento para administración oral
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение